Big Pharma has enjoyed an exceptional stretch of performance lately, reversing what had been a relatively rare period of underperformance brought on by overdone fears over this sector's ability to continue to grow. While the recovery in Pfizer's (NYSE:PFE) valuation was valid, the question now is whether the shares have significant room left to move. Given a relatively weak growth profile, investors shouldn't expect these strong returns to continue on all that much longer.
Please continue here:
http://www.investopedia.com/stock-analysis/052113/after-big-rally-pfizer-might-need-some-rest-pfe-bmy-mrk-rhhby.aspx
Investopedia: After A Big Rally, Pfizer Might Need Some Rest
0 comments:
Post a Comment